Viking Global Investors
ORIC icon

Viking Global Investors’s Oric Pharmaceuticals ORIC Stock Holding History

Viking Global Investors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.8M Sell
5,824,533
-748,158
-11% -$8.49M 0.21% 68
2025
Q4 		$53.8M Sell
6,572,691
-9
-0% -$104 0.14% 72
2025
Q3 		$78.9M Hold
6,572,700
– – 0.2% 67
2025
Q2 		$66.7M Hold
6,572,700
– – 0.19% 73
2025
Q1 		$36.7M Buy
6,572,700
+2,141,692
+48% +$18.7M 0.12% 78
2024
Q4 		$35.8M Buy
4,431,008
+431,008
+11% +$3.95M 0.12% 77
2024
Q3 		$41M Hold
4,000,000
– – 0.15% 75
2024
Q2 		$28.3M Hold
4,000,000
– – 0.11% 75
2024
Q1 		$55M Buy
+4,000,000
New +$47.5M 0.2% 71

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors's ORIC Position: Q1 2026 in Review

Viking Global Investors reduced its Oric Pharmaceuticals (ORIC) stake by 11% in Q1 2026, selling an estimated $8.49M and leaving 5,824,533 shares worth $73.8M. The position accounts for 0.21% of the portfolio, ranked #68.

Viking Global Investors first reported a position in ORIC in Q1 2024 and has held it in 9 quarters since. The position peaked at $78.9M in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Viking Global Investors held 5,824,533 shares of Oric Pharmaceuticals worth $73.8M as of Q1 2026.
  • Viking Global Investors sold 748,158 Oric Pharmaceuticals shares in Q1 2026, an estimated $8.49M.
  • Oric Pharmaceuticals made up 0.21% of Viking Global Investors's portfolio in Q1 2026, its #68 holding.
  • Viking Global Investors first reported a position in Oric Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Viking Global Investors's Oric Pharmaceuticals position peaked at $78.9M in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Viking Global Investors's 13F filing for Q1 2026, filed 15 May 2026.